Applied DNA announces notice of allowance for U.S. patent covering Linea RNAP

Applied DNA Sciences received a Notice of Allowance from the United States Patent and Trademark Office for patent application 18/302,247, entitled “Compositions and Methods for RNA Synthesis.” The resulting patent will cover the composition of the Company’s chemically modified RNA polymerase enzyme branded Linea RNAP, with expected patent protection into 2041. Linea RNAP is a core component of the Company’s Linea IVT platform that empowers mRNA manufacturers to produce better mRNA faster via a simplified mRNA production workflow with reduced or eliminated double-stranded RNA contamination. Applied DNA acquired the technology underlying the Linea RNAP via its acquisition of Spindle Bio, Inc. in July 2023.